Investors sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading on Wednesday. $121.04 million flowed into the stock on the tick-up and $196.11 million flowed out of the stock on the tick-down, for a money net flow of $75.07 million out of the stock. Of all stocks tracked, Johnson & Johnson had the 0th highest net out-flow for the day. Johnson & Johnson traded up $0.93 for the day and closed at $130.43

Several analysts recently commented on the stock. ValuEngine lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Tuesday, May 22nd. TheStreet raised shares of Johnson & Johnson from a “c+” rating to a “b” rating in a research note on Friday, May 18th. Jefferies Financial Group set a $145.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Sunday, July 15th. Credit Suisse Group set a $151.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Tuesday, June 12th. Finally, Sanford C. Bernstein assumed coverage on shares of Johnson & Johnson in a research note on Wednesday, June 27th. They set a “market perform” rating and a $129.00 target price for the company. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have given a buy rating to the company’s stock. Johnson & Johnson presently has an average rating of “Hold” and a consensus target price of $142.34.

The company has a current ratio of 1.65, a quick ratio of 1.33 and a debt-to-equity ratio of 0.47. The firm has a market cap of $350.79 billion, a PE ratio of 18.28, a P/E/G ratio of 1.99 and a beta of 0.73.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 17th. The company reported $2.10 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.06 by $0.04. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The business had revenue of $20.83 billion for the quarter, compared to analyst estimates of $20.39 billion. During the same quarter in the previous year, the business earned $1.83 earnings per share. The firm’s revenue was up 10.6% compared to the same quarter last year. equities research analysts forecast that Johnson & Johnson will post 8.14 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 11th. Stockholders of record on Tuesday, August 28th will be issued a dividend of $0.90 per share. The ex-dividend date is Monday, August 27th. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.69%. Johnson & Johnson’s dividend payout ratio is currently 49.32%.

Hedge funds have recently added to or reduced their stakes in the company. TT International increased its stake in Johnson & Johnson by 254.1% in the 1st quarter. TT International now owns 136,518 shares of the company’s stock valued at $15,930,000 after buying an additional 97,969 shares during the period. Eagle Global Advisors LLC increased its stake in Johnson & Johnson by 1.6% in the 1st quarter. Eagle Global Advisors LLC now owns 77,460 shares of the company’s stock valued at $9,927,000 after buying an additional 1,221 shares during the period. Trexquant Investment LP increased its stake in Johnson & Johnson by 28.2% in the 1st quarter. Trexquant Investment LP now owns 22,542 shares of the company’s stock valued at $2,889,000 after buying an additional 4,959 shares during the period. NuWave Investment Management LLC acquired a new position in Johnson & Johnson in the 4th quarter valued at approximately $680,000. Finally, Great West Life Assurance Co. Can increased its stake in Johnson & Johnson by 1.9% in the 1st quarter. Great West Life Assurance Co. Can now owns 3,784,116 shares of the company’s stock valued at $485,495,000 after buying an additional 72,159 shares during the period. Institutional investors and hedge funds own 66.20% of the company’s stock.

Johnson & Johnson Company Profile (NYSE:JNJ)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: What is the NASDAQ?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.